vimarsana.com
Home
Live Updates
Central Review Board - Breaking News
Pages:
Latest Breaking News On - Central review board - Page 1 : vimarsana.com
Oncolys BioPharma : Achievement of Primary Endpoint for Efficacy in the Phase2 Clinical Trial for Telomelysin-Radiation Combination Therapy -October 16, 2023 at 02:09 am EDT
NB: this is a summary translation of the press release original drafted in Japanese for the disclosure required in compliance.
Japan
Japanese
Oncolys-biopharma
Japan-esophageal-society
Primary-endpoint
Clinical-trial
Radiation-combination-therapy
Local-complete-response
Central-review-board
Endoscopic-findings
Local-response-rate
Esophageal-cancer
vimarsana © 2020. All Rights Reserved.